Тargeted therapy for CF patients with F508del/F508del genotype
نویسندگان
چکیده
منابع مشابه
Gene therapy for CF.
Background: Transcription factors regulate gene expression by interacting with their specific DNA binding sites. Some transcription factors, particularly those involved in transcription initiation, always bind close to transcription start sites (TSS). Others have no such preference and are functional on sites even tens of thousands of base pairs (bp) away from the TSS. The Cyclic-AMP response e...
متن کاملIvacaftor Therapy in CF Patients: Single Center Experience
Ivacaftor is the first novel cystic fibrosis pharmaceutical that acts at the molecular level to potentiate cystic fibrosis transmembrane conductance regulator (CFTR) function and was first approved for clinical use in 2012. We are sharing our single center experience of five patients: four from pediatric age group and one adult patient. All patients had both subjective and objective improvement...
متن کاملAirways reactivity in patients with CF.
Airways reactivity, hyper-reactivity, and hyper-responsiveness are terms used to describe airways for which there appears to be increased bronchial smooth muscle tone or responsiveness. Some patients with cystic fibrosis (CF) have concomitant asthma causing airway hyperresponsiveness as manifested by recurrent acute symptoms of dyspnea that is impressively responsive to an inhaled beta 2 agonis...
متن کاملClinical Outcome of CF Patients with CF Related Diabetes: Do We Need to Change Our Policy?
Background: Many studies have shown that CFRD has a negative impact on CF prognosis. Current guidelines advise to screen for CFRD with an OGTT yearly from the age of 10 12. In our center we do not routinely screen for CFRD because the OGTT is cumbersome and not an ideal screening test. We therefore want to exclude unfavourable clinical evolution due to late diagnosis. Methods: 23 CF patients wi...
متن کاملResponse-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.
The optimal duration of treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype 6 is unknown. This study was aimed at determining treatment response on the basis of rapid virological response (RVR) of HCV genotype 6 in comparison with genotypes 1 and 3. Sixty-six treatment naïve patients were treated with PEG-IFN-α2a (180 μg/week) plu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Russian Pulmonology
سال: 2019
ISSN: 2541-9617,0869-0189
DOI: 10.18093/0869-0189-2019-29-2-235-238